TL;DR
This week's developments mark a decisive shift toward high-efficacy, patient-friendly oral regimens that directly challenge established injectables and daily dosing protocols. Head-to-head Phase 3 readouts in plaque psoriasis and Type 2 diabetes demonstrate that oral small molecules can comfortably outperform current blockbuster therapies. Meanwhile, a major long-acting HIV milestone introduces the first once-weekly single-tablet regimen, even as global containment efforts for a rapidly expanding Ebola outbreak are threatened by geopolitical friction.
Next-Generation Oral Small Molecules Dismantle the Injectable Efficacy Trade-Off
Next-generation oral small molecules are successfully dismantling the historic efficacy trade-offs that forced patients to choose between the convenience of a pill and the superior potency of an injection.
"...more than 35% of zasocitinib-treated patients achieving complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib..." — Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study
"In ACHIEVE-3, Foundayo 17.2 mg drove 57.1% greater relative reduction in A1C..." — Obesity and Diabetes Incretin Pipeline: Next-Gen Oral GLP-1 Foundayo Outperforms Oral Semaglutide in Phase 3
In mid-June, Takeda announced that its highly selective oral TYK2 inhibitor zasocitinib achieved clear superiority over Bristol Myers Squibb's blockbuster deucravacitinib in adults with moderate-to-severe plaque psoriasis Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study. This direct triumph mirrors Eli Lilly's presentation at the American Diabetes Association sessions, where its oral GLP-1 receptor agonist Foundayo demonstrated substantial statistical superiority over oral semaglutide across all primary endpoints Obesity and Diabetes Incretin Pipeline: Next-Gen Oral GLP-1 Foundayo Outperforms Oral Semaglutide in Phase 3
. By proving that oral therapies can outperform established industry benchmarks without requiring complex dosing restrictions, these treatments are poised to reshape primary-care prescribing habits.
What to watch: Watch whether Takeda can leverage this superior head-to-head data to rapidly capture market share from Sotyktu upon regulatory filing and approval.
Ultra-Convenient Dosing Regimens Redefine Chronic Disease Management
The clinical management of chronic viral infections is transitioning toward ultra-convenient, long-acting oral options that drastically reduce daily treatment anxiety for patients.
"By advancing this investigational novel once-weekly oral regimen of islatravir and lenacapavir, we aim to bring forward a new long-acting oral option that, if approved, would represent the first of its kind with less frequent dosing and further expand options for people living with HIV..." — Gilead and Merck Once-Weekly Oral HIV Regimen Meets Phase 3 Endpoints
In early June, Gilead Sciences and Merck announced positive topline results from two pivotal Phase 3 trials, ISLEND-1 and ISLEND-2, evaluating a once-weekly oral single-tablet combination of islatravir and lenacapavir Gilead and Merck Once-Weekly Oral HIV Regimen Meets Phase 3 Endpoints. The trials proved that switching to this once-weekly regimen successfully maintained viral suppression at Week 48, establishing statistical non-inferiority to standard daily therapies (https://www.gilead.com/news/news-details/2026/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment). Shifting the burden of HIV care from a daily routine to a single weekly dose represents a profound psychological victory for patients, potentially boosting long-term adherence and reducing stigma.
What to watch: Watch for the presentation of detailed Phase 3 data at an upcoming scientific congress to evaluate the long-term safety and tolerability of this once-weekly regimen.
Geopolitical Disputes Threaten to Undermine Urgent Outbreak Containment
International diplomatic friction over travel restrictions is threatening to overshadow and disrupt the coordinated global response to a rapidly expanding, rare viral epidemic.
"...the Trump administration is asking European countries to impose travel restrictions on people who have recently been in Central African countries affected by the Ebola outbreak to prevent any potential spread of the disease during the World Cup, which will start tomorrow in the United States." — Bundibugyo Ebola Outbreak Nears 600 Cases as Geopolitical Travel Row Escalates Ahead of World Cup
In mid-June, the Democratic Republic of Congo reported that the confirmed case count for the Bundibugyo Ebola outbreak has escalated to 598, resulting in 115 deaths Bundibugyo Ebola Outbreak Nears 600 Cases as Geopolitical Travel Row Escalates Ahead of World Cup. Rather than fostering international collaboration, this surge has ignited a sharp dispute, with European authorities flatly rejecting U.S. pressure to impose travel bans ahead of the World Cup (https://www.cidrap.umn.edu/ebola/ebola-case-count-nears-600-feds-ask-travel-restrictions-ahead-world-cup). When geopolitical posturing takes precedence over localized containment and vaccine distribution, vulnerable border regions face heightened transmission risks while critical public health resources remain bottlenecked.
What to watch: Watch whether CEPI's fast-tracked funding can accelerate clinical testing of Moderna's mRNA candidate or IAVI's single-dose vaccine to halt the outbreak before it expands further.
What surprised us
- An oral small molecule can completely clear plaque psoriasis better than a blockbuster biologic. Historically, patients accepted that oral therapies like Sotyktu were convenient but less effective than injectable biologics. Takeda's zasocitinib flipped this script by delivering complete skin clearance (PASI 100) in over 35% of patients—more than 2.5 times the response rate of deucravacitinib Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study
.
- Lilly’s Foundayo bypasses the strict fasting rules of older oral peptides while crushing them in efficacy. Novo Nordisk's oral semaglutide requires strict food and water restrictions to work. Foundayo, as a non-peptide small molecule, has no such limits and still delivered up to a 73.6% greater relative weight loss in the ACHIEVE-3 head-to-head trial Obesity and Diabetes Incretin Pipeline: Next-Gen Oral GLP-1 Foundayo Outperforms Oral Semaglutide in Phase 3
.
- The official Ebola case count might be missing more than half the actual epidemic. While the DRC government officially tracks nearly 600 cases, a modeling study published in The Lancet Infectious Diseases estimated that undetected transmission in volatile provinces could mean the true case count is already well over 1,000 Bundibugyo Ebola Outbreak Nears 600 Cases as Geopolitical Travel Row Escalates Ahead of World Cup
.